Oxytocin Combo Extended Mouse Life 73%; Semaglutide Slowed Aging 9% [Best Read]
Plus time-restricted eating's IGF-1 drop, pulsed Yamanaka factors rejuvenating mouse neurons, and GlyNAC restoring strength in older adults.
In my work as a Silicon Valley based startup executive and longevity researcher, I track the gap between what the labs are publishing and what's actually worth adding to your protocol. Here's what stood out this week — with the numbers that matter.
Oxytocin plus an Alk5 blocker stretched frail male mouse lifespan 73% [ScienceAlert]
A UC Berkeley team combined oxytocin with an Alk5 (TGF-β receptor) inhibitor in old, frail mice and extended median lifespan by up to 73% in males. The effect was strongly sex-dependent — female mice did not see the same lasting benefit, a recurring theme in aging research that complicates translation. The combo targets stem-cell renewal and inflammatory signaling rather than a single pathway, consistent with the field's shift toward multi-hallmark intervention. It's a mouse result, but a 73% gain in already-frail animals is among the largest reported and worth tracking as it moves toward human-relevant dosing.
Semaglutide slowed biological aging 9% on the DunedinPACE clock in a 2026 trial [Medical News Today]
In a randomized trial in adults living with HIV, semaglutide slowed the pace of biological aging by roughly 9% on the DunedinPACE epigenetic clock versus placebo. The same GLP-1 class has posted hard outcome data elsewhere: in a large kidney trial all-cause mortality fell 20%, and tirzepatide cut cardiovascular death or worsening heart failure by 38% in the SUMMIT trial. Researchers stress this is an early aging signal, not proof of reversal — the clock measures pace, not rewind. A five-year ARPA-H study (VITAL-H, $38M, 726 adults in their 60s) will now test semaglutide head-to-head against rapamycin and dapagliflozin. For protocol builders already weighing a GLP-1 for metabolic reasons, the epigenetic data is a reason to watch this space closely.
20 days of time-restricted eating dropped IGF-1 sharply — but pushed fasting glucose up [Diseases]
In a 20-day controlled trial in obese young women, time-restricted feeding significantly lowered IGF-1 (p<0.001) — the growth-signaling pathway tied to slower aging across animal models. The catch: fasting blood glucose rose significantly in the same group (p=0.001), a reminder that compressing your eating window isn't uniformly clean metabolically. Alternate-day modified fasting behaved differently, underscoring that protocol design matters more than the label "fasting." For biohackers chasing lower IGF-1, time-restricted eating looks effective — but pair it with glucose monitoring rather than assuming every marker moves the right way.
Three Yamanaka factors, pulsed not continuous, reversed memory aging in mice [Communications Biology]
Researchers cyclically expressed three Yamanaka factors (OSK) only in the cortical neurons of aged mice and saw reversed age-related epigenetic markers plus measurably better memory performance. Critically, only cyclic — not continuous — dosing worked; continuous expression failed to deliver cognitive gains and risks erasing cell identity. This pulsed, tissue-selective logic is the same one behind the first human partial-reprogramming effort: Life Biosciences received FDA clearance in January 2026 to test OSK gene therapy in optic-nerve patients. This is frontier mouse-and-clinic science, not a protocol input yet — but reprogramming is moving from petri dish to patient faster than most expected.
GlyNAC for 24 weeks restored glutathione and lifted strength in older adults [Baylor College of Medicine]
In a randomized trial, older adults taking glycine plus N-acetylcysteine (GlyNAC) for 16 to 24 weeks corrected glutathione deficiency, lowered oxidative stress, and improved mitochondrial function, muscle strength, gait speed, and cognition versus placebo. Some physical-function measures moved toward those of matched younger adults. The benefits faded within 12 weeks of stopping, so this is a maintenance intervention, not a one-time fix. Of the supplement data this week, GlyNAC has the broadest human outcome footprint — cheap precursors, multiple hard endpoints, and a clear redox mechanism.
One gram of omega-3 daily shaved up to ~3.8 months off biological age over three years [Nature Aging]
In the 777-participant DO-HEALTH trial, 1 g/day of omega-3 slowed several DNA-methylation clocks (PhenoAge, GrimAge2, DunedinPACE), with effects equal to roughly 2.9 to 3.8 months of slower aging over three years. Adding 2,000 IU/day vitamin D and a simple home exercise program produced additive benefit on PhenoAge. The effect sizes are modest, but these are cheap, low-risk inputs with decades of safety data behind them. For a longevity protocol, omega-3 plus vitamin D plus regular resistance and cardio is about as close to a free lunch as the epigenetic-clock literature offers.